Frontlight ResearchEarly access
What researchers published on Myasthenia gravis
5,934 papers, newest first.
Showing 20 of 144
Trial resultLong-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).Frontiers in neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.Expert opinion on biological therapy
In plain wordsRead moreRead the paper on PubMedRandomised trialManagement of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial.JAMA neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.JAMA neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialHospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.Journal of medical economics
In plain wordsRead moreRead the paper on PubMedRandomised trialUsability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.Advances in therapy
In plain wordsRead moreRead the paper on PubMedRandomised trialHealth-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.Journal of neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialProteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.Journal of translational medicine
In plain wordsRead moreRead the paper on PubMedRandomised trialPathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.Journal of neurology, neurosurgery, and psychiatry
In plain wordsRead moreRead the paper on PubMedRandomised trialClinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).Journal of neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEvaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.European journal of neurology
In plain wordsRead moreRead the paper on PubMedTrial resultPhase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis.Scientific reports
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.JAMA neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet (London, England)
In plain wordsRead moreRead the paper on PubMedRandomised trialImpact of a ketogenic diet on clinical outcomes and immunological markers in myasthenia gravis: A randomized pilot study.Journal of autoimmunity
In plain wordsRead moreRead the paper on PubMedRandomised trialDigital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG-MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue.Muscle & nerve
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.Neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy and safety of efgartigimod in the treatment of impending myasthenic crisis.Frontiers in immunology
In plain wordsRead moreRead the paper on PubMedTrial resultSingle-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.Med (New York, N.Y.)
In plain wordsRead moreRead the paper on PubMed